-
A Phase 1 Study of LNCB74 in Advanced Solid Tumors
NCT06774963 ·
Phase: Phase 1 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Pennsylvania: Philadelphia, Pittsburgh
-
A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors
NCT06695845 ·
Phase: Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Pennsylvania: Horsham
-
A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
NCT06586957 ·
Phase: Phase 1 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Pennsylvania: Philadelphia, Pittsburgh
-
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
NCT04657068 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Pennsylvania: Philadelphia
-
A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
NCT06778863 ·
Phase: Phase 1 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Pennsylvania: Philadelphia
-
A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation
NCT05877599 ·
Phase: Phase 1 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Pennsylvania: Pittsburgh
-
A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
NCT06395519 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Pennsylvania: Philadelphia
-
BI-1808 as a Single Agent and With Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies(Keynote-D20)
NCT04752826 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Pennsylvania: Philadelphia
-
DESTINY-PANTUMOUR04
NCT07124000 ·
Phase: Not specified ·
Ages: 18 Years to 130 Years ·
Sex: All (male and female)
· Pennsylvania: Philadelphia
-
Distance-Based Exercise to Preserve Function and Prevent Disability
NCT07059884 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Pennsylvania: Butler, Indiana, New Castle, Pittsburgh
-
FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors
NCT07216105 ·
Phase: Phase 1 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Pennsylvania: Philadelphia
-
FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC
NCT06303505 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Pennsylvania: Pittsburgh
-
Lead-212 PSV359 Therapy for Patients With Solid Tumors
NCT06710756 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years to 90 Years ·
Sex: All (male and female)
· Pennsylvania: Pittsburgh
-
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
NCT03452774 ·
Phase: Not specified ·
Ages: No age limits stated ·
Sex: All (male and female)
· Pennsylvania: Philadelphia
-
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
NCT06545942 ·
Phase: Phase 1 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Pennsylvania: Philadelphia
-
SynKIR-110 for Mesothelin Expressing Ovarian Cancer, Cholangiocarcinoma or Mesothelioma
NCT05568680 ·
Phase: Phase 1 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Pennsylvania: Philadelphia
-
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
NCT04585750 ·
Phase: Phase 1, Phase 2 ·
Ages: 12 Years and older ·
Sex: All (male and female)
· Pennsylvania: Philadelphia, Pittsburgh, York